Join StocksJar.com -Get 7 Days Free trial

Viatris (VTRS) Stock Price & AI Analysis

NASDAQ
USA

$12.72

-$1.20
(-1.52%)

Subscribe to get
AI Score

  • Market Cap 14.98B
  • Volume 5.01M
  • Avg Volume 7.82M
  • Target Price $15.57
  • 52W Range 9.56 - 13.62
  • RSI (14) 49.55
  • Beta 0.95
  • PEG Ratio 0
  • SMA 20 -2.47
  • SMA 50 4.36
  • SMA 200 9.37
  • Insider Owner 2.44%
  • Insider Trans -3.23%
  • Institution Owner 79.61%
  • Institution Trans -2.17%
  • Short Interest 20.71%
  • EPS next Y -0.93

Viatris Company Profile

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.
Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Viatris | Latest news

Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?

Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?

Viatris VTRS, a global healthcare company, is scheduled to report first-quarter results on May 9,...

Zacks - 7 months ago

Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down

Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down

Viatris Inc. VTRS delivered adjusted earnings of 67 cents per share in the first quarter of 2024,...

Zacks - 7 months ago

Viatris Inc. (VTRS): David Einhorn’s Top Stock Pick

Viatris Inc. (VTRS): David Einhorn’s Top Stock Pick

We recently compiled a list of the David Einhorn’s Stock Portfolio: Top 10 Stocks to Buy. In this article, we are going to take a look at where Viatris...

Insider Monkey - 2 months ago

Viatris Inc. (VTRS): A Strategic Shift in Healthcare Investments

Viatris Inc. (VTRS): A Strategic Shift in Healthcare Investments

We recently published a list of 8 Stocks Under $20 To Invest In Now. In this article, we are going...

Insider Monkey - 2 months ago

Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise

Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise

Viatris (VTRS) stock down after posting weaker-than-expected results from its generics business....

Zacks - 9 months ago

Unveiling Viatris (VTRS)'s Value: Is It Really Priced Right? A Comprehensive...

Unveiling Viatris (VTRS)'s Value: Is It Really Priced Right? A Comprehensive...

Viatris Inc (NASDAQ:VTRS) has seen a 3.5% daily gain, a 3-month gain of 4.33%, and an Earnings Per...

GuruFocuscom - 1 year ago

Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent

Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent

Viatris Inc. VTRS and partner Ocuphire Pharma, Inc. OCUP together announced the FDA approval of...

Zacks - 1 year ago

Why Is Viatris Inc. (VTRS) the Best Dividend-Paying Stock to Buy Under $15?

Why Is Viatris Inc. (VTRS) the Best Dividend-Paying Stock to Buy Under $15?

We recently compiled a list of the 10 Best Dividend-Paying Stocks Under $15. In this article, we are...

Insider Monkey - 4 months ago

Viatris (VTRS)'s Technical Outlook is Bright After Key Golden Cross

Viatris (VTRS)'s Technical Outlook is Bright After Key Golden Cross

From a technical perspective, Viatris Inc. (VTRS) is looking like an interesting pick, as it just...

Zacks - 1 year ago

Here’s Why Greenlight Decided to Repurchase Viatris (VTRS)

Here’s Why Greenlight Decided to Repurchase Viatris (VTRS)

Greenlight Capital, an investment management firm, released its fourth quarter 2023 investor letter,...

Insider Monkey - 10 months ago